Theaflavin attenuates ischemia–reperfusion injury in a mouse fatty liver model

• Published in: Biochemical and biophysical research communications 2012-01, Vol.417 (1), p.287-293
• Main Authors: Luo, Xiao-Yu, Takahara, Terumi, Hou, Jiangang, Kawai, Kengo, Sugiyama, Toshiro, Tsukada, Kazuhiro, Takemoto, Masumi, Takeuchi, Masao, Zhong, Liang, Li, Xiao-Kang
• Format: Article
• Language: English
• Subjects: Animals; Antioxidants - administration & dosage; Apoptosis - drug effects; Biflavonoids - administration & dosage; Catechin - administration & dosage; Cell Line; Cytokines - antagonists & inhibitors; Cytokines - biosynthesis; Fatty liver; Fatty Liver - drug therapy; Fatty Liver - pathology; Fatty Liver - physiopathology; Hepatocytes - drug effects; Ischemia–reperfusion injury; Liver Transplantation; Macrophages; Male; Mice; Mice, Inbred C57BL; NAFLD; Non-alcoholic Fatty Liver Disease; Oxidative stress; Reperfusion Injury - drug therapy; Reperfusion Injury - pathology; Reperfusion Injury - physiopathology; RNA, Messenger - antagonists & inhibitors; RNA, Messenger - biosynthesis; Theaflavin; Tissue Donors; Tumor Necrosis Factor-alpha - metabolism
• ISSN: 0006-291X; 1090-2104
• DOI: 10.1016/j.bbrc.2011.11.102

► This is the first time to use theaflavin in fatty liver related disease animal model. ► We form a proper model to imitate fatty liver transplantation in clinic. ► Theaflavin can decrease production of reactive oxygen species (ROS). ► Theaflavin can effectively inhibit macrophages accumulation. ► Theaflavin can suppress inflammatory cytokines production. The incidence of non-alcoholic fatty liver disease (NAFLD) has been increasing, and there is a shortage of liver donors, which has led to the acceptance of steatotic livers for transplantation. However, steatotic livers are known to experience more severe acute ischemia–reperfusion (I/R) injury than normal livers upon transplantation. In the present study, we investigated the role of theaflavin, a polyphenol substance extracted from black tea, in attenuating acute I/R injury in a fatty liver model. We induced I/R in normal and steatotic livers treated with or without theaflavin. We also separated primary hepatocytes from the normal and steatotic livers, and applied RAW264.7 cells, a mouse macrophage cell line, that was pretreated with theaflavin. We observed that liver steatosis, oxidative stress, inflammation and hepatocyte apoptosis were increased in the steatotic liver compared to the normal liver, however, these changes were significantly decreased by theaflavin treatment. In addition, theaflavin significantly diminished the ROS production of steatotic hepatocytes and TNF-α production by LPS-stimulated RAW264.7 cells. We concluded that theaflavin has protective effects against I/R injury in fatty livers by anti-oxidant, anti-inflammatory, and anti-apoptotic mechanisms.